Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction

Study Identifier
195263-007
CT.gov Identifier
NCT01979887
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dry Eye
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    40+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Participants characterized as with or without Meibomian Gland Dysfunction.
    Exclusion Criteria:
    * Lid heating therapy, therapeutic gland expression, or meibomian gland probing within 12 months of enrollment * Contact lens use in the 30 days prior to enrollment * Lid hygiene within 48 hours prior to enrollment * Use of eye makeup within 8 hours of enrollment * Eyelash growth-stimulating products within 30 days prior to enrollment * Use of systemic vitamins and/or systemic supplements containing omega 3 fatty acids within 60 days of enrollment * Use of systemic anti-histamines within 30 days prior to enrollment.

    Protocol Summary

    This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.

    Study Locations

    Location
    Status
    Location
    Houston, Texas, United States
    Status
    Not applicable
    Location
    London, United Kingdom
    Status
    Not applicable